A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: procedure (653), etiquette (1), practice (614)

Binimetinib-Encorafenib

Description
Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or metastatic BRAF V600 mutation-positive melanoma where the
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

Pembrolizumab (200mg)

Description
Regimen Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (200mg) • Head and Neck – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended in in adult
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-200mg.pdf

Nivolumab

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab Regimen • Head and Neck – Nivolumab Indication • The treatment of recurrent or metastatic squamous cell
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab.pdf

Pembrolizumab (400mg) head and neck

Description
Chemotherapy Protocol HEAD AND NECK CANCER Pembrolizumab (400mg) Regimen • Head and Neck – Pembrolizumab (400mg) Indication • Pembrolizumab is recommended in in adult
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Pembrolizumab-400mg-head-and-neck.pdf

HSCTAlemtuzumabBusulphan-08-Fludarabine-VUD-Methotrexate-GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (8 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-8-Fludarabine-VUD-Methotrexate-GvHD.pdf

HSCTAlemtuzumabBusulphan-10-Fludarabine-VUD-Methotrexate-GvHD

Description
Chemotherapy Protocol HAEMATOLOGY – HSCT ALLOGRAFT ALEMTUZUMAB-BUSULFAN (10 doses)-FLUDARABINE-METHOTREXATE (GvHD) Volunteer Unrelated Donor (VUD) CONDITIONING This regimen will only
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Transplant/HSCTAlemtuzumabBusulphan-10-Fludarabine-VUD-Methotrexate-GvHD.pdf

Ipilimumab-Nivolumab Ver1

Description
Chemotherapy Protocol MESOTHELIOMA IPILIMUMAB-NIVOLUMAB Regimen • Mesothelioma – Ipilimumab-Nivolumab Indication • Nivolumab in combination with ipilimumab is indicated for the first-line
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Mesothelioma/Ipilimumab-Nivolumab-Ver1.pdf

Fulvestrant-Ribociclib

Description
Chemotherapy Protocol Breast Cancer Fulvestrant-Ribociclib Regimen • Breast Cancer – Fulvestrant-Ribociclib Indication • Fulvestrant and ribociclib is indicated for oestrogen receptor-positive
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Fulvestrant-Ribociclib.pdf

E(100)CT

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100) Regimen (E100CT) • Breast Cancer – Cyclophosphamide-Docetaxel-Epirubicin (100) (E100CT) Indication • Neo-adjuvant / adjuvant
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/E100CT.pdf

Cyclophosphamide-Docetaxel-Epirubicin (100)-Fluorouracil (FE100CT)

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-DOCETAXEL-EPIRUBICIN (100)- FLUOROURACIL Regimen (FE100CT) • Breast Cancer – Cyclophosphamide-Docetaxel-Epirubicin (100)-Fluorouracil (FE100CT) Indication • Neo
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Docetaxel-Epirubicin-100-Fluorouracil.pdf
591 to 600 of 698
Previous … 58 59 60 61 62 … Next